These promising preclinical results prompted the initiation of a Phase I, double-blind, placebo-controlled clinical trial (NCT01041222) starting in 2010, to assess the safety and tolerability of intrathecally administered ASO 333611 in SOD1 ALS patients [60]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.